Get the Stockscreener App
4.265
5.92%
-0.295
Immatics N V stock is traded at $4.265, with a volume of 284.70K.
It is down -5.92% in the last 24 hours and up +3.62% over the past month.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
See More
Previous Close:
$4.56
Open:
$4.54
24h Volume:
284.70K
Relative Volume:
0.40
Market Cap:
$619.91M
Revenue:
$58.49M
Net Income/Loss:
$-105.04M
P/E Ratio:
-3.2815
EPS:
-1.2997
Net Cash Flow:
$-13.78M
1W Performance:
-6.54%
1M Performance:
+3.62%
6M Performance:
-49.94%
1Y Performance:
-61.00%
1-Day Range:
$4.15
$4.54
1-Week Range:
$3.94
$4.83
52-Week Range:
$3.30
$13.77
Immatics N V Stock (IMTX) Company Profile
Compare IMTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMTX
Immatics N V
|
4.28 | 619.91M | 58.49M | -105.04M | -13.78M | -1.2997 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.41 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.85 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.20 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.62 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
223.50 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Immatics N V Stock (IMTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-24 | Initiated | Piper Sandler | Overweight |
| Nov-02-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Mar-24-23 | Initiated | Bryan Garnier | Buy |
| Nov-20-20 | Initiated | BofA Securities | Buy |
| Sep-22-20 | Initiated | Goldman | Buy |
| Jul-27-20 | Initiated | SVB Leerink | Outperform |
| Jul-24-20 | Initiated | Jefferies | Buy |
View All
Immatics N V Stock (IMTX) Latest News
Immatics NV earnings missed by €0.07, revenue topped estimates - Investing.com
Immatics NV reports results for the quarter ended March 31Earnings Summary - TradingView
Immatics: Q1 Earnings Snapshot - San Antonio Express-News
IMTX Sees Revenue Decline, Highlights Advances in Melanoma Thera - GuruFocus
Immatics Reports Increased Q1 2025 Loss Amid Rising R&D Costs - TipRanks
Immatics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Immatics Announces First Quarter 2025 Financial Results and Business Update - GlobeNewswire
Immatics (IMTX) Projected to Post Quarterly Earnings on Tuesday - Defense World
(IMTX) Proactive Strategies - news.stocktradersdaily.com
Immatics US opens 100,000-square-foot Stafford cell-therapy manufacturing plant (PHOTOS) - The Business Journals
Guggenheim Capital LLC Takes $101,000 Position in Immatics (NASDAQ:IMTX) - Defense World
Immatics (NASDAQ:IMTX) Shares Sold by JPMorgan Chase & Co. - Defense World
Are Immatics N.V (IMTX) shares a good deal now? - uspostnews.com
Immatics Announces Upcoming Oral and Poster Presentation on IMA2 - GuruFocus
Immatics N.V. to Present Updated Data on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting - Nasdaq
Immatics Announces Upcoming Oral and Poster Presentation on - GlobeNewswire
Breakthrough Melanoma Treatment IMA203 : Phase 1b Results and Phase 3 Progress Coming to ASCO 2025 - Stock Titan
Short Interest in Immatics (NASDAQ:IMTX) Declines By 20.7% - Defense World
Immatics N.V (NASDAQ: IMTX): Moving Toward A Higher Share Price - Stocksregister
(IMTX) Long Term Investment Analysis - news.stocktradersdaily.com
Immatics N.V (NASDAQ: IMTX): Can’t Stop The Stock’s Slide? - stocksregister.com
Immatics FY2025 EPS Estimate Lowered by Cantor Fitzgerald - The AM Reporter
FY2025 EPS Estimates for Immatics Decreased by Analyst - Defense World
Immatics (NASDAQ:IMTX) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World
Financial Contrast: Novonesis A/S (OTC:NVZMY) and Immatics (NASDAQ:IMTX) - Defense World
Research Analysts Set Expectations for Immatics Q1 Earnings - The AM Reporter
Q1 Earnings Estimate for Immatics Issued By Leerink Partnrs - Defense World
Immatics Reports Strong 2024 Financial Results and Progress - TipRanks
Immatics N.V.: Trading Below Cash, But Not Without Reason (NASDAQ:IMTX) - Seeking Alpha
Immatics NV earnings beat by €0.74, revenue topped estimates - Investing.com
Immatics NV reports results for the quarter ended December 31Earnings Summary - TradingView
Immatics Announces Full Year 2024 Financial Results and Business Update - GlobeNewswire
Immatics Advances Cancer Immunotherapy with Phase 3 Trial and Strong Financials - TipRanks
Breakthrough: Immatics' Melanoma Treatment Achieves 54% Response Rate as Phase 3 Trial Advances - Stock Titan
Immatics (NASDAQ:IMTX) Trading Down 5.3% – Time to Sell? - Defense World
IMMATICS N.V Earnings Preview: Recent $IMTX Insider Trading, Hedge Fund Activity, and More - Nasdaq
(IMTX) Trading Report - Stock Traders Daily
Immatics (IMTX) Projected to Post Earnings on Thursday - Defense World
Short Interest in Immatics (NASDAQ:IMTX) Declines By 11.9% - Defense World
TCR Therapy Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Developing Drugs for the Market Entry | DelveInsight - GlobeNewswire Inc.
Y Intercept Hong Kong Ltd Buys New Position in Immatics (NASDAQ:IMTX) - Defense World
Immatics (NASDAQ:IMTX) adds US$66m to market cap in the past 7 days, though investors from a year ago are still down 61% - Simply Wall St
TCR Therapy Clinical Trial Pipeline Accelerates as 80+ - GlobeNewswire
Immatics N.V (IMTX) Recovers -2.54% From Low: Are We There Yet? - Stocks Register
Financial Metrics Unveiled: Immatics N.V (IMTX)’s Key Ratios in the Spotlight - The Dwinnex
Immatics (NASDAQ:IMTX) Sets New 1-Year Low – What’s Next? - Defense World
(IMTX) Trading Signals - Stock Traders Daily
Immatics (NASDAQ:IMTX) Reaches New 1-Year LowHere's What Happened - MarketBeat
abrdn plc Buys 114,479 Shares of Immatics (NASDAQ:IMTX) - MarketBeat
New Strong Buy Stocks for February 12th - Yahoo Finance
Immatics (NASDAQ:IMTX) Trading Down 4.7% – What’s Next? - Defense World
Immatics N V Stock (IMTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.19%
0.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):